Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
List of Authors:Strauer,Bodo-Eckehard; Yousef, Muhammad; Schannwell, Christiana,M.
Despite accumulated evidence that intracoronary bone marrow cell (BMC) therapy may be beneficial in acute myocardial infarction, there are only limited data available on the effectiveness of BMCs in chronic heart failiure.The aim of this study was to quantitatively investigate ventricular hemodynamics, geometry, and contractility as well as the long-term clinical outcome of BMC treated patients with reduced left ventricular ejection fraction (LVEF) due to chronic ischemic cardiomyopathy.
Patients (n=391, LVEF<35%) with chronic ischemic cardiomyopathy were enrolled in the present study. Of these, 191 patients (mean NYHA class 3.22) underwent intracoronary BMC therapy. The control group (mean NYHA class 3.06) consisted of 200 patients with comparable LVEF. Assessment of hemodynamics at rest and exercise, quantitative ventriculography, spiroergometry, 24h Holter ECG, late potentials, and heart rate variability were analysed. Over 3 months to 5 years after intracoronary BMC therapy there was a significant improvement in hemodynamics (e.g. LVEF, cardiac index), exercise capacity, oxygen uptake, and LV contractility. Importantly, there was a significant decrease in long-term mortality in the BMC treated patients compared with the control group.
Intracoronary BMC therapy improves ventricular performance, quality of life and survival in patients with heart failure. The effects were present when BMC were administered in addition to standard therapeutic regimen. No side effects were observed.
Our mission: To reduce the burden of cardiovascular disease
© 2018 European Society of Cardiology. All rights reserved